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Abstract
Background: As HIV and hepatitis C (HCV) share some modes of transmission co-infection is not uncommon. This 
study used a population-based sample of HIV and HCV tested individuals to determine the prevalence of HIV/HCV co-
infection, the sequence of virus diagnoses, and demographic and associated risk factors.
Methods: Positive cases of HIV were linked to the combined laboratory database (of negative and positive HCV 
antibody results) and HCV reported cases in British Columbia (BC).
Results: Of 4,598 HIV cases with personal identifiers, 3,219 (70%) were linked to the combined HCV database, 1,700 
(53%) of these were anti-HCV positive. HCV was diagnosed first in 52% of co-infected cases (median time to HIV 
identification 3 1/2 years). HIV and HCV was diagnosed within a two week window in 26% of cases. Among individuals 
who were diagnosed with HIV infection at baseline, subsequent diagnoses of HCV infection was independently 
associated with: i) intravenous drug use (IDU) in males and females, Hazard Ratio (HR) = 6.64 (95% CI: 4.86-9.07) and 
9.76 (95% CI: 5.76-16.54) respectively; ii) reported Aboriginal ethnicity in females HR = 2.09 (95% CI: 1.34-3.27) and iii) 
males not identified as men-who-have-sex-with-men (MSM), HR = 2.99 (95% CI: 2.09-4.27).
Identification of HCV first compared to HIV first was independently associated with IDU in males and females OR =
2.83 (95% CI: 1.84-4.37) and 2.25 (95% CI: 1.15-4.39) respectively, but not Aboriginal ethnicity or MSM. HIV was
identified first in 22%, with median time to HCV identification of 15 months;
Conclusion: The ability to link BC public health and laboratory HIV and HCV information provided a unique 
opportunity to explore demographic and risk factors associated with HIV/HCV co-infection. Over half of persons with 
HIV infection who were tested for HCV were anti-HCV positive; half of these had HCV diagnosed first with HIV 
identification a median 3.5 years later. This highlights the importance of public health follow-up and harm reduction 
measures for people identified with HCV to prevent subsequent HIV infection.
Background
HIV and hepatitis C (HCV) are major burdens on the
health care system in Canada and share some common
modes of transmission. HCV co-infection is estimated to
occur in 20% of Canadians infected with HIV [1] and 50-
90% of HIV-positive persons who use drugs intravenously
[2-4]. Compared to HIV mono-infected individuals, HIV/
HCV co-infected groups are characterized by a higher
prevalence of injection drug use, poverty, and psychiatric
disorders [5].
Co-infection affects disease progression related to both
agents [6-12] and complicates treatment [13-15]. The rate
of liver cirrhosis is up to six times higher in HIV co-
infected persons than HCV mono-infected [12,16-19].
Effective anti-retroviral therapies have improved the life
expectancy of persons with HIV so that persons co-
infected with chronic HCV survive to develop HCV cir-
rhosis.
Clinical management and treatment of co-infected
patients is challenging and complex [13-15]. Abnormal
hepatic function is one of the most common complica-
tions occurring among HIV-infected individuals receiv-
ing anti-retroviral therapy [14,20,21]. Consensus
guildelines for co-infection state all HIV-infected individ-
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u a l s  s h o u l d  b e  s c r e e n e d  f o r  H CV ,  a n d  t h o s e  w i t h  c o -
infection should be considered for anti-HCV treatment,
even though response to anti-HCV therapy is lower in co-
infected patients [14,16,20,21]. As antiretoviral hepato-
toxicity may be increased in the presence of HCV infec-
tion, ideally HCV treatment should be intiated before
anti-HIV therapy when HIV infection is stable [22]. How-
ever, treating HIV first is clearly indicated when CD4
lymphocyte count is very low (<200 cells/microL) [13].
Although data on HIV/HCV c o-infection is a vailable
from defined study cohorts such as persons who use
intravenous drugs (IDU) and men who have sex with men
(MSM) there is little population-based data. All confir-
matory HIV testing in British Columbia (BC) and 95% of
anti-HCV testing is performed at the Provincial Public
Health Reference laboratory. First positive HIV tests in
BC are reported to the STI/HIV Prevention and Control
D i v i s i o n  a t  B C  C e n t r e  f o r  D i s e a s e  C o n t r o l  ( B C C D C ) .
Since 1995 more than 6,000 cases of HIV have been
reported, and risk factor information at the time of HIV
identification collected. All newly identified cases of
HCV, who are resident in BC and not previously reported
elsewhere in Canada, are reported by the five regional
public health authorities (Figure 1) into the BC integrated
Public Health Information System (iPHIS), which is coor-
dinated at BCCDC. Approximately 65,000 antibody reac-
tive cases of HCV have been reported into iPHIS since
1992.
The aim of this study was to link positive cases of HIV
with both anti-HCV positive cases and anti-HCV nega-
tive testers identified in the BC surveillance and labora-
tory systems in order to determine prevalence of HIV/
HCV co-infection. The sequence of virus diagnosis,
demographic characteristics and associated risk factors at
the time of HIV infection were determined. This linkage
enables the estimation of the current and projected bur-
den of disease in order to guide prevention, testing and
care programs, and appropriate resource allocation.
Methods
Data sources
The STI/HIV Prevention and Control database (HIV
dataset) which contains all anti-HIV positive individuals
(confirmed by HIV Western Blot) was linked to the com-
bined BCCDC laboratory HCV testing database and
reported HCV cases in iPHIS (HCV dataset). The time-
frame of the data linkage was from January 1st 1995 to
December 31st 2008.
HCV antibody testing was performed using second- or
third-generation enzyme-linked immunosorbent assays
(EIA) including Organon Teknika (UBI) v2.0, v2.1, v4.0
(Organon Teknika, Durham, North Carolina) and Abbott
AxSYM HCV 3.0 (Abbott Diagnostics, Chicago, Illinois).
S pec i m e n s  r e a c t i v e  f o r  a n t i - HCV  w e r e  r e t es t ed  b y  t h e
second or third generation Recombinant Immunoblot
Assay (Chiron, Emeryville, California) until July 1999 to
confirm EIA specificity. Between April 1997 and Febru-
ary 2004, Abbott AxSYM HCV 3.0 anti-HCV reactive
specimens were re-tested by either Organon Teknika
(UBI) v4.0 or Ortho EcI (Ortho, Canada). Thereafter,
anti-HCV screening was performed on the ADVIA Cen-
taur (initially Bayer, Canada, now Siemens, Canada) and
anti-HCV reactive samples re-tested on the Abbott
Architect (Abbott, Canada). Only specimens reactive by
both manufacturers' tests were considered to be anti-
HCV reactive. As HCV RNA test results (qualitative
COBAS AMPLICOR HCV Test v2.0 (Roche Diagnostic
Systems, Mississauga, Canada) were only available on a
subset of HCV antibody positive cases these data were
not included in our analysis. Data elements include first
and last name, personal health number, date of birth, sex,
location (health region of residence of the subject at the
time of HIV virus identification), ethnicity (self- or clini-
cian-reported), date each virus was identified, and expo-
sure category(ies) at the time HIV infection was
identified.
Data management and confidentiality
The HIV and HCV datasets were linked on personal
identifiers; after which nominal information was perma-
nently deleted and a unique study code was allocated. To
maintain confidentiality the linkage process was per-
formed by computer programmed algorithms without
displaying personal identifiers. All datasets used in the
linkage process with retained identifiers were perma-
nently deleted leaving only the final, linked, anonymized
dataset to be used for the statistical analyses. Data manip-
ulation and analyses were performed using SAS version
9.1.3 for Windows (SAS Institute, Cary, NC).
All first positive HIV cases, identified from January 1st
1995 to December 31st 2008 with personal identifiers,
were linked with the combined HCV dataset. Those with
HCV and HIV first identified within 2 weeks were con-
sidered simultaneous identification. Ethical approval was
received from the UBC Clinical Research Ethics Board.
Statistical analysis
Cases aged <15 years and non-BC residents were
excluded. Univariate logistic regression was used to com-
pare linked and unlinked subjects. Univariate and multi-
variate Cox proportional hazard regression were used to
estimate the hazard ratios (HR) and 95% confidence
intervals of HIV/HCV co-infection among individuals
with HIV mono-infection at baseline. Univariate and
multivariate logistic regression were used to assess the
association between the sequence of virus identification
and explanatory variables among co-infected individuals;
odds ratios (OR) and 95% Wald confidence intervals wereBuxton et al. BMC Public Health 2010, 10:225
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estimated. Multivariate regression analyses were con-
ducted separately by sex as predictive factors were differ-
ent for males and females, covariates included age,
ethnicity, health authority of residence at HIV infection
and IDU for both sexes; MSM was included for males.
Results
A total of 6,288 HIV cases were eligible for analysis; 4,598
(73%) had personal identifiers and therefore were poten-
tially linkable to the combined HCV dataset. The HCV
dataset comprised test results from 914,442 individuals,
of whom 69,339 (7.6%) were anti-HCV antibody positive.
In total, 3,219 (70%) HIV cases were linked to the HCV
dataset (Figure 2). The HIV positive population that was
linked to the HCV dataset were younger than those not
linked; mean age 37.9 vs. 39.3 (t = 4.00, p < 0.0001). In
univariate analysis those linked were more likely to be
female (O.R. 2.01, 95% CI 1.70-2.38), Aboriginal (O.R.
1.96, 95% CI 1.60-2.41), and to not reside in Vancouver
Coastal Health Region (O.R. 1.90, 95% CI 1.67-2.16).
Of the 3,219 persons with HIV that were linked to the
HCV dataset, 1,700 (53%) were co-infected; i.e. at least
27% of all HIV cases. Within those co- infected, HCV was
diagnosed first in 52% of cases, with a median time to
subsequent HIV identification 3 1/2 years; 26% were
diagnosed at about the same time (± 2 weeks); HIV was
identified first in 22%, with median time to HCV identifi-
cation of 15 months (Figure 2).
Among individuals who were HIV mono-infected at
baseline, subsequent diagnosis of HCV (compared to per-
sons without a HCV infection diagnosis) using univariate
analysis was significantly associated with a younger age at
HIV identification, reported Aboriginal ethnicity,
Figure 1 British Columbia map of health authorities.Buxton et al. BMC Public Health 2010, 10:225
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reported IDU and not being identified as MSM in males
(Table 1).
The Cox proportional hazard assumption was tested by
including the interactions of predictors and log survival
time as time dependent covariates in the model. The
results suggested that the proportionality assumption of
the model was not violated. In multivariable Cox regres-
sion model of individuals who were HIV mono-infected
Figure 2 HIV data linked with HCV dataset; January 1, 1995 to December 31, 2008.Buxton et al. BMC Public Health 2010, 10:225
http://www.biomedcentral.com/1471-2458/10/225
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Table 1: HIV mono-infected cases at baseline linked to HCV dataset January 1, 1995 to December 31, 2008
HCV not detected
(%)
HCV co-infected
(%)
Unadjusted
HR
95% Confidence
Limits
N 1519 379
Age at HIV 0.97 0.96-0.98
Mean 38.6 34.3
Std 11.67 9.05
Range 15-82 15-61
Sex
Male 1234 (81.2) 265 (69.9) 1.00
Female 274 (18.0) 112 (29.6) 1.61 1.26-2.04
Transgender 1 (0.1) 1 (0.3)
Unknown/
missing
10 (0.7) 1 (0.3)
Ethnicity
Non-
Aboriginal
1292 (85.1) 234 (61.7) 1.00
Aboriginal 136 (9.0) 79 (20.8) 2.72 2.11-3.52
Unknown/
missing
91 (6.0) 66 (17.4)
Health 
Authority
Vancouver 
Coastal
829 (54.6) 191 (50.4) 1.00
Fraser 432 (28.4) 108 (28.5) 1.04 0.80-1.36
Interior 86 (5.7) 21 (5.5) 1.07 0.65-1.76
Northern 52 (3.4) 10 (2.6) 1.16 0.59-2.27
Vancouver 
Island
118 (7.8) 45 (11.9) 1.17 1.23-2.40
Missing 2 (0.1) 4 (1.1)
Male Female Male Female Male Female Male Female
MSM
Yes 796
(64.5)
-4 7
(17.7)
-1 . 0 0
No 438
(35.5)
-2 1 8
(82.3)
- 5.40 3.90-
7.49
-
IDU
Yes 122
(9.9)
37
(13.5)
169
(63.8)
81
(72.3)
10.33 10.94 7.76-
13.77
6.61-
18.10
No 1112
(90.1)
237
(86.5)
96
(36.2)
31
(27.7)
1.00 1.00Buxton et al. BMC Public Health 2010, 10:225
http://www.biomedcentral.com/1471-2458/10/225
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at baseline (Table 2), males aged 45+ at HIV identification
were less likely to become co-infected compared to males
aged 15-24, (HR 0.55, 95% CI: 0.31-0.97), but age was not
significant for females. Males and females who reported
IDU were more likely to become co-infected: HR 6.64,
95% CI: 4.86-9.07 and HR 9.76, 95% CI: 5.76-16.54
respectively. Females reporting Aboriginal ethnicity were
twice as likely to become co-infected (HR 2.09, 95% CI:
1.34-3.27); ethnicity was not significant for males. Males
not identified as MSM were more likely to become co-
infected (HR 2.99, 95% CI: 2.09-4.27).
Diagnosis of HCV before HIV in univariate analysis of
co-infected individuals was significantly associated with
older age, female sex, reported IDU and not being identi-
fied as MSM in males (Table 3). In the separate multivari-
ate logistic regression models for males and females,
HCV diagnosis before HIV was significantly associated
with age and IDU in both sexes (Table 4). The majority of
persons co-infected reported IDU as the major risk fac-
tor; a small proportion (6.2%) of co-infected males
reported both MSM and IDU and 5.4% reported MSM
only (Table 5).
Discussion
This study provides important new information from a
population-based sample of HIV and HCV tested indi-
viduals. We are able to provide a robust estimate of those
w h o  h a v e  bee n  i n f ec t ed  wi t h  bo t h  HCV  a n d  HIV ,  t h e
order of virus identification and associated risk factors.
Previous studies which assess co-infection have typically
been cross-sectional surveys or longitudinal cohorts fol-
lowing persons who inject drugs or are MSM and there-
fore results are more likely to be population specific or
affected by selection bias.
This study uses anti-HCV positivity to define HCV
infection and co-infection. We recognize that approxi-
mately 25% (range 15% to 45%) of infected individuals
will clear infection spontaneously [23]. As HCV-RNA
testing was available only in a subgroup of anti-HCV pos-
itive individuals, we are unable to confirm active HCV
infection in individuals diagnosed with HCV. Therefore
our study overestimates the number of individuals who
are actually HCV/HIV co-infected.
The HIV/HCV co-infection rate in our HIV seroposi-
tive sample is high compared to other studies [1]; over
half of persons with HIV who were tested for HCV were
found to be HCV positive. In a population sample per-
sons who are at highest risk for HCV infection such as
IDU may be more likely to be tested and therefore over-
estimate co-infection. IDU was independently associated
with HCV co-infection in both sexes, but reported
aboriginal ethnicity was significant in females only.
Among a cohort of IDU aged <30 years in Vancouver,
coinfection at baseline was independently associated with
Table 2: Adjusted hazard ratios (Cox regression) for risk of co-infection
Adjusted HR* 95% Confidence
Limits
Male
(N = 137)
Female
(N = 354)
Male Female
Age group at HIV
25-34 years vs. 
15-24 years
0.77 1.19 0.47-1.27 0.72-1.97
35-44 years vs. 
15-24 years
0.78 1.55 0.48-1.27 0.89-2.70
45+ years vs. 
15-24 years
0.55 0.99 0.31-0.97 0.39-2.49
Health Authority (HA) vs. Vancouver Coastal HA
Fraser HA 0.81 1.06 0.58-1.12 0.62-1.81
Interior HA 0.89 1.41 0.48-1.66 0.59-3.39
Northern HA 0.73 0.51 0.32-1.69 0.16-1.68
Vancouver Island 
HA
1.10 2.23 0.70-1.71 1.28-3.89
Aboriginal Yes vs. No 1.29 2.09 0.88-1.88 1.34-3.27
IDU Yes vs. No 6.64 9.76 4.86-9.07 5.76-16.54
MSM No vs. Yes 2.99 2.09-4.27
*Separate model for males and females. Models include age at HIV, IDU, aboriginal ethnicity, Health Authority and MSM (for males only)Buxton et al. BMC Public Health 2010, 10:225
http://www.biomedcentral.com/1471-2458/10/225
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Table 3: Order of virus identification for individuals with HIV/HCV co-infection, January 1st 1995- December 31st, 2008
HIV first
(%)
HCV first
(%)
Unadjusted
OR
95% Confidence
Limits
N 379 876
Age at HIV 1.05 1.04-1.07
Mean 34.3 38.6
Std 9.05 9.31
Range 15-61 18-75
Sex
Male 265 (69.9) 559 (63.8) 1.00
Female 112 (29.6) 313 (35.7) 1.33 1.02-1.72
Transgender 1 (0.3) 3 (0.3)
Unknown/
missing
1 (0.3) 1 (0.1)
Ethnicity
Non-Aboriginal 234 (61.7) 570 (65.1) 1.00
Aboriginal 79 (20.8) 244 (27.8) 1.27 0.94-1.70
Unknown/
missing
66(17.4) 62 (7.1)
Health 
Authority
Vancouver 
Coastal
191 (50.4) 335 (38.2) 1.00
Fraser 108 (28.5) 205 (23.4) 1.08 0.81-1.45
Interior 21 (5.5) 65 (7.4) 1.77 1.05-2.98
Northern 10 (2.6) 74 (8.5) 4.22 2.13-8.36
Vancouver 
Island
45 (11.9) 195 (22.3) 2.47 1.71-3.58
Missing 4 (1.1) 2 (0.2)
Male Female Male Female Male Female Male Female
MSM
Yes 47
(17.7)
-5 5
(9.8)
-1 . 0 0
No 218
(82.3)
-5 0 4
(90.2)
- 1.98 1.30-
3.01
-
IDU
Yes 169
(63.8)
81
(72.3)
474
(84.8)
266
(85.0)
3.17 2.17 2.26-
4.46
1.28-
3.62
No 96
(36.2)
31
(27.7)
85
(15.2)
47
(15.0)
1.00 1.00Buxton et al. BMC Public Health 2010, 10:225
http://www.biomedcentral.com/1471-2458/10/225
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being female, aboriginal ethnicity, involvement in sex
trade, older age, greater number of years injecting [4].
Our study population is based on persons who are sero-
positive for HIV rather than IDU, therefore the results are
not directly comparable.
Our study sample does not represent systematic sam-
pling of the population, but is based on all laboratory
confirmed HIV infected cases during the study period
that were then linked to individuals who had undergone
HCV serologic testing. The sample is therefore biased to
those who are offered and undergo testing. Although
there is an effort to make testing acceptable and available
in clinics and through outreach throughout BC, there
may be geographic differences.
To reduce the bias for order of detection, 1995 was cho-
sen as the start date, excluding only 11 HIV cases. HCV
has been reportable and testing routinely available since
1992; thus 32,428 individuals prior to 1992 were
excluded. However, these would be included if HCV test-
ing occurred at a later date. In addition, 80 positive HIV
cases were excluded as aged <15 years or non-BC resi-
dence.
Between January 1995 to April 1997 anti-HCV testing
involved screening with the slightly less sensitive second
generation anti-HCV test followed by immunoblot con-
firmation. Since April 1997 to the end of the study period
all testing involved screening with the more sensitive 3rd
generation anti-HCV assay and confirmation by a second
manufacturer's enzyme immunoassay. Only specimens
reactive by both manufacturers' tests were considered to
be anti-HCV reactive. Therefore it is unlikely that
changes in anti-HCV serological testing over the course
of the study impacted HCV diagnostic accuracy.
Our results may have been affected by changes in data
quality over time. HIV became a reportable infection in
BC in 2003; at this time enhanced regional public health
follow-up of individuals having a new positive HIV test
was established resulting in improved ascertainment of
ethnicity and exposure categories. The quality of identi-
fier data used for data linkage has also changed over time,
and is most complete after 2003. Therefore co-infection
of HIV cases identified prior to 2003 may be under-
reported, or bias introduced in subgroup analyses.
The use of partial identifiers, pseudonyms, or non-
nominal testing (a testing option introduced in 2003 for
HIV) also affects our ability to link data accurately. In
studies which require data linkage, some vulnerable and
high risk populations are more likely to be excluded due
to lack of personal identifiers or difficulty in obtaining
risk factor information. Therefore our study may under-
estimate the number of HIV cases who are HCV co-
infected.
The HIV positive population that had not been tested
for HCV differed by age, sex and ethnicity; therefore, our
Table 4: Adjusted ORs (multivariate logistic regression) of HCV first vs. HIV first
Adjusted OR* 95% Confidence
Limits
Male
(N = 726)
Female
(N = 392)
Male Female
Age group at HIV
25-34 years vs. 15-24 years 1.79 2.20 0.85-3.77 1.15-4.19
35-44 years vs. 15-24 years 3.22 3.73 1.56-6.66 1.87-7.42
45+ years vs. 15-24 years 7.11 8.15 3.24-15.59 2.88-23.09
Health Authority (HA) vs. Vancouver Coastal HA
Fraser HA 1.16 1.02 0.76--1.77 0.54-1.90
Interior HA 2.12 1.61 1.00-4.49 0.57-4.54
Northern HA 2.57 5.83 0.99-6.72 1.64-20.78
Vancouver Island HA 2.67 1.18 1.57-4.54 0.61-2.28
Aboriginal Yes vs. No 1.35 1.27 0.85-2.15 0.76-2.12
IDU Yes vs. No 2.83 2.25 1.84-4.37 1.15-4.39
MSM No vs. Yes 1.48 0.90-2.44
*Separate model for males and females. Models include age at HIV, IDU, aboriginal ethnicity, Health Authority and MSM (for males only)Buxton et al. BMC Public Health 2010, 10:225
http://www.biomedcentral.com/1471-2458/10/225
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study results cannot be generalized beyond the linked
population. As IDU is a well known transmission route
for HCV, persons who use intravenous drugs may be
more likely to be offered and accept HCV testing. Thus
we may have overestimated the odds of IDU in co-infec-
tion, but the strength of the association is clear.
Our study population uses an HIV dataset to drive the
linkage therefore the major exposure categories were
determined according to HIV risk rather than HCV risk.
Although the risk factors are similar, they may change
over time and differ at the time of HCV co-infection diag-
nosis from those identified at the time of HIV diagnosis.
Ascertainment of accurate exposure categories such as
IDU and MSM may not be elicited during follow-up due
to social desirability bias.
Our study reflects the initial diagnosis of HIV and
HCV; however it cannot determine when the infection
occurred nor confirm the order of infection. Over 80% of
persons acutely infected with HCV are asymptomatic and
may have undiagnosed HCV infection for decades [24].
The order of virus detection will also be affected by avail-
ability and patterns of testing as well as the patient's will-
ingness to be tested for HCV and/or HIV.
If testing for both viruses occured within 2 weeks we
c o n s i d e r e d  t h i s  t o  b e  s i m u l t a n e o u s  i d e n t i f i c a t i o n .
Patients may have been tested for HIV and HCV due to
reported risk factors, or the testing of second virus may
immediately follow identification of the first. Some
patients maybe diagnosed with co-infection as part of a
diagnostic work up for mild or moderate disease, or when
they present in the emergency room with opportunistic
infections [25].
Although the predominant risk factor for HCV infec-
tion reported in HIV seropositive men is IDU [26,27],
acquisition of HCV in HIV seropositive MSM without a
history of IDU is increasingly reported [28]. In this group,
HCV seroconversion has been associated with other sex-
ually transmitted infections such as syphilis or lym-
phogranuloma venereum and/or sexual practices causing
mucosal damage such as fisting [28-30]. We found 5.4% of
co-infected males reported MSM and no history of IDU.
This is likely an underestimate due to lack of HCV testing
in this group but suggests that sexual transmission of
HCV is occurring in this population. MSM who are HIV
infected should be informed that they may be at risk for
HCV even if they do not use intravenous drugs and
offered testing, especially if considering HIV treatment
[13-15].
HCV was identified first in about half of those who
were co-infected, with a median time to HIV detection of
about 3 1/2 years. This highlights the need for effective
public health follow-up when HCV is identified. HCV is
more easily transmitted percutaneously and has a higher
prevalence in IDU than HIV. Miller et al studied co-infec-
Table 5: Major risk factor categories HIV/HCV co-infection, BC January 1, 1995- December 31st, 2008
MALES
HCV first (%)
n = 559
HIV/HCV Same (%)
n = 325
HIV first (%)
n = 265
All
n = 1,149
IDU 436 (78.0) 247 (76.0) 154 (58.1) 837 (72.8)
MSM 17 (3.0) 13 (4.0) 32 (12.1) 62 (5.4)
MSM/IDU 38 (6.8) 18 (5.5) 15 (5.7) 71 (6.2)
Heterosexual Contact 35 (6.3) 26 (8.0) 33 (12.1) 94 (8.2)
Nil identified/
Unknown
28 (5.0) 18 (5.5) 28 (10.6) 74 (6.4)
Other 5 (0.9) 3 (0.9) 3 (1.1) 11 (1.0)
FEMALES
HCV first (%)
n = 313
HIV/HCV Same (%)
n = 120
HIV first (%)
n = 112
All
n = 545
IDU 266 (85.0) 100 (83.3) 81 (72.3) 447 (82.0)
Heterosexual Contact 32 (10.2) 14 (11.7) 22 (19.6) 68 (12.5)
Nil identified/
Unknown
13 (4.2) 5 (4.2) 9 (8.0) 27 (5.0)
Other 2 (0.6) 1 (0.8) 0 (0.0) 3 (0.6)Buxton et al. BMC Public Health 2010, 10:225
http://www.biomedcentral.com/1471-2458/10/225
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tion in a cohort of young IDU and found accessing meth-
adone maintenance therapy in the previous 6 months was
protective from seroconversion of the second infection
[4]. Identification of HCV provides an opportunity for
public health interventions including testing for other
blood borne pathogens such as HIV, and offering appro-
priate immunizations and harm reduction measures.
Engagement through harm reduction such as providing
clean needles and other drug use paraphernalia and
methadone maintenance can decrease the risk of subse-
quent HIV infection [31].
Conclusion
The high prevalence of co-infection supports the need for
HCV screening in HIV positive populations. It is impor-
tant to ensure HIV and HCV testing is accessible and
offered in gender and culturally appropriate manner. The
ability to link BC public health and laboratory HIV and
HCV information provided a unique opportunity to
explore demographic and risk factors associated with
HIV/HCV co-infection in a large population-based sam-
ple. Over half of persons with HIV infection who were
tested for HCV were shown to be anti-HCV positive, and
half of these had HCV identified first with HIV identifica-
tion a median 3.5 years later. This study highlights the
importance of public health follow-up and harm reduc-
tion measures for people identified with HCV as a means
to prevent subsequent HIV infection.
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